Clinical trial NCT04891133: EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial
Official title: European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
PHASE3
Conditions: COVID-19
Emerging Infectious Disease
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
Collaborators: name: Institut National de la Santé Et de la Recherche Médicale, France
name: Epidemiological and Clinical Research Information Network
First posted: 2021-05-18
Enrollment: 290
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: EU SolidAct is a randomized, multifactorial, adaptive platform trial for COVID-19 and emerging infectious diseases and pandemics. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to hospital with COVID-19. The platform is designed for running phase 2 and phase 3 trials, and with modular data capture (end point/safety data, biobanking, add-on studies) depending on the capacity of participating sites. The study consists of two parts with different primary end points depending on disease stage: EU SolidAct part A includes hospitalized patients with moderate disease, whereas EU SolidAct part B includes hospitalized patients with severe and critical disease.

Detailed description: There is an urgent need for developing an adaptive pan-European research platform for rapid and coordinated investigation of new candidate drugs during ongoing pandemics. EU-SolidAct is an Adaptive Platform Trial master protocol developed for evaluating drug interventions in hospitalized patients with COVID-19. While this master protocol is developed for therapeutic interventions in hospitalized patients, it could also form the basis for trial protocols on other interventions and/or in non-hospitalized populations. The protocol is additionally developed to facilitate a joint European response to the challenge of evaluating interventions during future epidemics. The described disease states and endpoints may need to be adapted to the epidemic in question.

EU-SolidAct is a European, multicentre, randomized, parallel, phase 2 and 3 platform trial on drug interventions, both new and repurposed, single or in combination, in hospitalized adult patients with moderate or severe COVID-19, as defined by the WHO Working Group on the Clinical Characterisation and Management of COVID-191. Participants with moderate disease (WHO score 4-5) will be eligible for EU-SolidAct Part A, whereas participants with severe/critical disease (WHO score 6-9) will be eligible for EU-SolidAct Part B. This might include participants progressing from Part A.

In Part A of phase 3 confirmatory trials, the primary objective is to determine the effect of therapeutic interventions on occurrence of disease progression, from moderate disease to severe/critical disease or death within 14 days. In Part B, the primary objective is to determine the effect of therapeutic interventions on occurrence of death within 60 days.

In phase 2 the default objective for both parts is to explore the effect of the therapeutic intervention on respiratory dysfunction at day 5. Other objectives, e.g. effect on virological outcomes may be considered based on the treatment mode of action.

In phase 3 trials, both superiority and non-inferiority hypotheses may be evaluated. In phase 2 trials, only superiority hypotheses will be evaluated. In addition to single treatments, combination of treatments could also be assessed through factorial design. EU-SolidAct is designed to be adaptive and to enable inclusion of hospitals in Europe and beyond, regardless of epidemic waves and available resources. This requires the master protocol to be modular, ranging from a core set of outcomes to more advanced data capture. Hospitals will access the study on different pre-set levels, ranging from a core set of clinical endpoints and safety measures, to a more advanced level with biobanking and possibilities for add-on studies

Eligibility criteria: \*\*EU SOLIDACT PLATFORM INCLUSION CRITERIA\*\*:

Participants are eligible to be included in the study only if all the following general inclusion (GI) criteria apply:

* GI1. ≥ 18 years of age
* GI2. Laboratory-confirmed SARS-CoV-2 infection (new infection or reinfection) as determined by PCR not more than 14 days old.
* GI3. Admitted to hospital
* GI4. Informed consent by the participant or legally authorized representative
* GI5A (SolidAct part A): Moderate disease state defined as hospitalised patients without oxygen therapy or oxygen by mask or nasal prongs needed, or
* GI5B (SolidAct part B): Severe/critical disease state defined as fulfilling at least one of the following criteria:

  1. SpO2\<90% on room air, or
  2. SpO2 90-94% with a downwards trend and/or signs of respiratory distress\*, or
  3. Need of oxygen by NIV (CPAP, BIPAP), high flow or non-rebreather mask, or
  4. Need of mechanical ventilation/ECMO

     * persistently increased respiratory rate, use of accessory muscles, inability to complete full sentences. Clinical judgement must be applied to determine whether a low oxygen saturation is indicative of disease progression or severity or is habitual for a given patient (i.e., with underlying chronic lung disease).

NIV=non-invasive ventilation. CPAP= Continuous Positive Airway Pressure, BPAP= Bi-level Positive Airway Pressure, ECMO = extracorporeal membrane oxygenation.

Additional inclusion criteria are given in the intervention-specific sub-protocols.

Note: these are based on the same criteria as in the WHO living guidelines recommending corticosteroid treatment for severe and critical COVID-195.

In addition, the following specific inclusion criteria apply:

SI-01. Immunocompromised patients defined as the presence of at least one of the following conditions9:

1. Hematological malignancy or pre-malignancy, except acute leukemia or history of lymphoma
2. Organ transplant recipients, except recipients of bone marrow or solid organ transplant last 6 months, or with transplant rejection last 6 months
3. HIV positive with CD4 count \< 350 cells and on stable antiretroviral therapy
4. Primary immunodeficiency
5. Rheumatoid arthritis, lupus, vasculitis, inflammatory bowel disease or other autoimmune disorder for which a patient is being treated with systemic immunosuppressive medication
6. Other specified cause, such as history of cancer, cancer treatment or other condition that in the opinion of the investigator could cause impaired host immunity

SI-02. Elevation of 2 or more inflammatory markers above the following cutoffs:

* Ferritin \> 700 ug/l
* LDH \> 400 U/L
* CRP \> 75 mg/L

Note: Carefully check exclusion criteria SE-01, SE-20 and SE-21 (immunosuppressive therapy), SE-22 (medical condition), SE-13 (neutropenia) and SE-14 (lymphopenia) for eligibility criteria.

Immunocompromised patients should receive appropriate SoC, including anti-SARS-CoV2 monoclonal antibodies or emerging antiviral treatment, if available and indicated by current treatment guidelines at time of inclusion.

EXCLUSION CRITERIA:

Participants are excluded from the study if any of the following general exclusion criteria (GE) apply:

* GE1. Anticipated transfer to another non-trial hospital within 72 hours
* Additional exclusion criteria, including prohibited medication, confounding trials and details on contraception and pregnancy are given in the intervention-specific sub-protocols

  * SE-01. Patients receiving Janus kinase (JAK) inhibitors (including baricitinib) for any indication at screening.
  * SE-20. Have received tocilizumab or sarilumab for any indication 4 weeks prior to screening.

Note: Tocilizumab as rescue therapy will be allowed in patients with clinical progression after inclusion, see section 6.8 concomitant medication. If tocilizumab or other immunosuppressive rescue therapy is started, IMP should be discontinued.

• SE-21. Patients with recent changes in immunosuppressive therapy that could interfere with the potential effect of baricitinib.

Note: An assessment of the total level of immunosuppression, hematological parameters (SE-13 and SE-14), drug half-lives, drug-drug interactions, and underlying medical conditions (SE-22) must be performed as part of the risk/benefit evaluation.

* Recipients of bone marrow transplant or solid organ transplant last 6 months, or with transplant rejection last 6 months, should not be included.
* Organ transplant recipients receiving triple immunosuppression can only be included if the anti-metabolite (mycophenolic acid or mTOR inhibitor) has been temporarily discontinued per clinical practice10. IMP should be discontinued once triple immunosuppression is restarted.

  * SE-22. Any medical condition that in the opinion of the investigator poses an inacceptable risk of serious infection or aggravation of the medical condition by participating in the trial.

Note: Patients with acute leukemia or history of lymphoma should not be included. Cancer patients under active treatment, HIV positive individuals with detectable HIV-RNA, or other patient group associated with high risk of serious infection or aggravation of the medical condition should only be included if, in the judgement of the investigator, the potential benefit outweighs the potential risk.

* SE-03. Have received dexamethasone 6 mg daily (or alternative regimens with equivalent of corticosteroids) for more than 4 days prior to screening as part of SoC for severe/critical COVID-19
* SE-04. Had COVID-related symptoms \> 21 days or hospitalized \> 7 days.
* SE-05. Strong inhibitors of organic anion transporter 3 \[OAT3\] (e.g., probenecid) that cannot be discontinued at study entry.
* SE-07. Have received any live vaccine within 4 weeks before screening, or intend to receive a live vaccine during the study (until day 90 (+/- 14 days)).

Note: Use of non-live (inactivated) vaccinations, including COVID-19 vaccinations, is allowed for all participants.

* SE-08. Are using or will use extracorporeal blood purification (EBP) device to remove proinflammatory cytokines from the blood such as a cytokine absorption or filtering device, for example, CytoSorb®.
* SE-09. Have diagnosis of current active tuberculosis (TB) or, if known, latent TB treated for less than 4 weeks with appropriate anti-tuberculosis therapy per local guidelines (by history only, no screening tests required).
* SE-10. Suspected serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking investigational product.
* SE-12. Have a history of venous thromboembolism (VTE) (deep vein thrombosis \[DVT\] and/or pulmonary embolism \[PE\]) within 12 weeks prior to randomization or have a history of recurrent (\>1) VTE (DVT/PE).
* SE-13. Neutropenia (absolute neutrophil count \<1000 cells/microliters).
* SE-14. Lymphopenia (absolute lymphocyte count \<200 cells/microliters).
* SE-15. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>5 times ULN.
* SE-16. Subjects with estimated glomerular filtration rate (eGFR) (Modification of Diet in Renal Disease \[MDRD\]) \<30 millilitre/minute/1.73 meters squared are excluded.
* SE-17. Known hypersensitivity to baricitinib or any of its excipients.
* SE-18. Are pregnant or breastfeeding, or intend to become pregnant or breastfeed during the study.

Note: Women of child bearing potential (WOCBP) can only be included based on a negative pregnancy test and WOCBP must comply with requirements regarding highly effective contraception. Refer to section 10.1 for contraception requirements.

• SE-19 Participation in any therapeutic clinical trials investigating immunomodulators for COVID-19

Primary outcomes:
measure: Occurrence of death within 60 days (primary end point, EU SolidAct part B)
timeFrame: 60 days
measure: Occurrence of disease progression within 14 days (primary end point, EU SolidAct part A)
timeFrame: 14 days
measure: SpO2/FiO2-ratio at day 5 (primary end point, phase 2 trials)
timeFrame: 5 days
Secondary outcomes:
measure: Occurrence of disease progression within 28 days (shared secondary end point for part A and B)
timeFrame: 28 days
measure: Time to sustained recovery (shared secondary end point for part A and B)
timeFrame: 90 days
measure: Time to first hospital discharge (shared secondary end point for part A and B)
timeFrame: 90 days
measure: Disease state at Day 15 and Day 29 (shared secondary end point for part A and B)
timeFrame: 28 days
measure: Time from randomization to recovery (shared secondary end point for part A and B)
timeFrame: 90 days
measure: SpO2/FiO2-ratio at Day 3, 5 and 8 (shared secondary end point for part A and B)
timeFrame: 8 days
measure: Viral clearance during hospitalization (shared secondary end point for part A and B)
timeFrame: Days 1, 3, 5, 8 and 15
measure: Occurrence of serious adverse events within 90 days (shared secondary end point for part A and B)
timeFrame: 90 days
measure: Patient related outcomes at day 90 (shared secondary end point for part A and B)
timeFrame: 90 days
Other outcomes:
measure: Changes in C-reactive protein from baseline
timeFrame: Days 1, 3, 5, 8, 15 and 22
measure: Changes in Ferritin from baseline
timeFrame: Days 1, 3, 5, 8, 15 and 22
measure: Changes in Lactate dehydrogenase from baseline
timeFrame: Days 1, 3, 5, 8, 15 and 22
measure: Changes in D-dimer from baseline
timeFrame: Days 1, 3, 5, 8, 15 and 22
measure: Changes in procalcitonin from baseline
timeFrame: Days 1, 3, 5, 8, 15 and 22
measure: Changes in neutrophils from baseline
timeFrame: Days 1, 3, 5, 8, 15 and 22
measure: Changes in lymphocytes from baseline
timeFrame: Days 1, 3, 5, 8, 15 and 22
measure: Changes in White Blood Cell Count from baseline
timeFrame: Days 1, 3, 5, 8, 15 and 22
Locations:
city: Innsbruck
country: Austria
facility: Medical University of Innsbruck (University Hospital for Neurosurgery)
city: Innsbruck
country: Austria
facility: Medical Unversity of Innsbruck (Joint Institute for Emergency Medicine and Critical Care)
city: Innsbruck
country: Austria
facility: Medical Unversity of Innsbruck (University Hospital for Anaesthesia and Intensive Care)
city: Brussels
country: Belgium
facility: Erasme Hospital
city: Brussels
country: Belgium
facility: UZ Brussel
city: Brussels
country: Belgium
facility: Cliniques Universitaires Saint-Luc
city: Brno
country: Czechia
facility: St Anne University Hospital
city: Amiens
country: France
facility: CHU Amiens Picardie (ICU)
city: Amiens
country: France
facility: CHU Amiens Picardie (ID)
city: Bordeaux
country: France
facility: CHU de Bordeaux / Hopital Pellegrin (ICU)
city: Bordeaux
country: France
facility: CHU de Bordeaux / Hopital Pellegrin (ID)
city: Colombes
country: France
facility: Louis Mourier (ID)
city: Colombes
country: France
facility: Lous Mourier (ICU)
city: Dijon
country: France
facility: CHU François Mitterrand
city: Lille
country: France
facility: CHU Lille - Hopital Roger Salengro -Pôle Rèanimaition
city: Lyon
country: France
facility: Hopital de la Croix - Rousse - HCL (ICU)
city: Lyon
country: France
facility: Hopital de la Croix - Rousse - HCL (ID)
city: Mulhouse
country: France
facility: GHRMSA Hopital Emile Muller (ICU)
city: Mulhouse
country: France
facility: GHRMSA Hopital Emile Muller (IM)
city: Paris
country: France
facility: Hôpital Saint-Antoine (ICU)
city: Paris
country: France
facility: Hôpital Saint-Antoine (ID)
city: Paris
country: France
facility: Hôpital Bichat - Claude Bernard (ICU)
city: Paris
country: France
facility: Hôpital Bichat - Claude Bernard (ID)
city: Bremen
country: Germany
facility: Gesundheit Nord gGmbH (GeNo)
city: München
country: Germany
facility: Technische Universität München (TUM) - Klinikum rechts der Isar
city: Athens
country: Greece
facility: Evangelismos Hospital
city: Athens
country: Greece
facility: Attikon University Hospital
city: Debrecen
country: Hungary
facility: University of Debrecen (Clinic for Infectology)
city: Pécs
country: Hungary
facility: University of Pécs
city: Szeged
country: Hungary
facility: University of Szeged (Pandemic Clinics)
city: Cork
country: Ireland
facility: Cork University Hospital
city: Dublin
country: Ireland
facility: St Vincent's University Hospital
city: Dublin
country: Ireland
facility: Mater Misericordiae University Hospital
city: Dublin
country: Ireland
facility: St James's Hospital, Dublin
city: Dublin
country: Ireland
facility: Beaumont Hospital, Dublin
city: Dublin
country: Ireland
facility: Tallaght University Hospital
city: Galway
country: Ireland
facility: University Hospital Galway
city: Limerick
country: Ireland
facility: University Hospital Limerick
city: Bagno A Ripoli
country: Italy
facility: Ospedale Santa Maria Annunziata, Malattie Infettive
city: Brescia
country: Italy
facility: ASST - Spedali Civili di Brescia - University of Brescia
city: Cagliari
country: Italy
facility: ATS Sardegna - PO SS Trinità, U.O.C. Malattie Infettive
city: Catanzaro
country: Italy
facility: Azienda Opsedaliera Universitaria Mater Domini, U.O. Malattie Infettive e Tropicali
city: Frosinone
country: Italy
facility: ASL Frosinone - Ospedale Fabrizio Spaziani, U.O.C. Medicina Interna
city: Latina
country: Italy
facility: Ospedale S.M. Goretti di Latina, U.O.C. Malattie Infettive
city: Legnano
country: Italy
facility: Ospedale Mater Salutis di Legnago, U.O.C. di Pneumologia
city: Legnano
country: Italy
facility: Ospedale Mater Salutis di Legnago, U.O.S. di Malattie Infettive
city: Milano
country: Italy
facility: ASST Santi Paolo e Carlo, S.C. Malattie Infettive
city: Napoli
country: Italy
facility: Azienda Ospedaliera Universitaria Vanvitelli, U.O.C. Malattie Infettive
city: Palermo
country: Italy
facility: AOU Policlinico "P. Giaccone", U.O.C. Malattie Infettive
city: Pesaro
country: Italy
facility: Azienda Ospedaliera Ospedali Riuniti Marche Nord, U.O.C. Malattie Infettive
city: Taranto
country: Italy
facility: ASL Taranto - Ospedale Oncologico San Giuseppe Moscati, U.O.C. Pneumologia
city: Torino
country: Italy
facility: AOU Città della Salute e Scienza Presidio Molinette
city: Trieste
country: Italy
facility: Azienda Sanitaria Universitaria Giuliano Isontina (ASU GI), S.C. Malattie Infettive
city: Verona
country: Italy
facility: IRCCS Ospedale Sacro Cuore Don Calabria, U.O.S. Malattie Infettive e Tropicali
city: Verona
country: Italy
facility: Azienda Ospedaliera Universitaria Integrata di Verona, U.O.C. Malattie Infettive e Tropicali
city: Luxembourg
country: Luxembourg
facility: Centre Hospitalier de Luxembourg
city: Drammen
country: Norway
facility: Drammen (Vestre Viken) Hospital
city: Grålum
country: Norway
facility: Østfold sykehuset i Kalnes
city: Lørenskog
country: Norway
facility: Akershus Universitetssykehus
city: Oslo
country: Norway
facility: Lovisenberg Diaconal Hospital
city: Oslo
country: Norway
facility: OUS Ullevål
city: Sandvika
country: Norway
facility: Bærum Hospital
city: Stavanger
country: Norway
facility: Stavanger University Hospital
city: Tromsø
country: Norway
facility: University Hospital North Norway
city: Trondheim
country: Norway
facility: St. Olavs Hospital
city: Tønsberg
country: Norway
facility: Vestfold Hospital
city: Abrantes
country: Portugal
facility: CHMT - Centro Hospitalar do Médio Tejo- Hospital de Abrantes
city: Coimbra
country: Portugal
facility: CHUC - Centro Hospitalar e Universitário de Coimbra
city: Faro
country: Portugal
facility: CHUA-Faro - Centro Hospitalar Universitário do Algarve
city: Lisboa
country: Portugal
facility: CHLC-HCC - Hospital Curry Cabral, Centro Hospitalar Universitário Lisboa Central
city: Lisboa
country: Portugal
facility: CHLN - Centro Hospitalar Universitário Lisboa Norte
city: Lisbon
country: Portugal
facility: CHLO - Centro Hospitalar de Lisboa Ocidental - HEM and HSFX
city: Lisbon
country: Portugal
facility: CHSJ - São João Hospital Center
city: Loures
country: Portugal
facility: HBA - Hospital Beatriz Ângelo
city: Bratislava
country: Slovakia
facility: University Hospital Bratislava, Kramare
city: Martin
country: Slovakia
facility: University Hospital Martin
city: Trebišov
country: Slovakia
facility: Nsp Trebisov, Svet Zdravia a.s.
city: Trenčín
country: Slovakia
facility: Faculty Hospital Trencin
city: Trnava
country: Slovakia
facility: University Hospital Trnava
city: Córdoba
country: Spain
facility: Hospital Universitario Reina Sofia
city: Jaén
country: Spain
facility: Hospital Universitario de Jaen
city: Madrid
country: Spain
facility: Hospital Universitario La Paz
city: Marbella
country: Spain
facility: Hospital Costa del Sol
city: Málaga
country: Spain
facility: Hospital Virgen de la Victoria
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen Macarena
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen del Rocio
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen de Valme
city: Ankara
country: Turkey
facility: Hacettepe Üniversitesi Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı (Site 1)
city: Ankara
country: Turkey
facility: Hacettepe Üniversitesi Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı (Site 2)
city: Ankara
country: Turkey
facility: Ankara Üniversitesi Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı
city: Istanbul
country: Turkey
facility: İstanbul Üniversitesi İstanbul Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı
city: İzmir
country: Turkey
facility: Dokuz Eylül Üniversitesi Tıp Fakültesi Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı
Study officials:
affiliation: Institut National de la Santé Et de la Recherche Médicale, France
name: Domique Costagliola, PhD
role: STUDY_CHAIR
affiliation: Hospital Universario La Paz, Madrid
name: Jose R Arribas, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Troseid M, Arribas JR, Assoumou L, Holten AR, Poissy J, Terzic V, Mazzaferri F, Bano JR, Eustace J, Hites M, Joannidis M, Paiva JA, Reuter J, Puntmann I, Patrick-Brown TDJH, Westerheim E, Nezvalova-Henriksen K, Beniguel L, Dahl TB, Bouscambert M, Halanova M, Peterfi Z, Tsiodras S, Rezek M, Briel M, Unal S, Schlegel M, Ader F, Lacombe K, Amdal CD, Rodrigues S, Tonby K, Gaudet A, Heggelund L, Mootien J, Johannessen A, Moller JH, Pollan BD, Tveita AA, Kildal AB, Richard JC, Dalgard O, Simensen VC, Balde A, de Gastines L, Del Alamo M, Aydin B, Lund-Johansen F, Trabaud MA, Diallo A, Halvorsen B, Rottingen JA, Tacconelli E, Yazdanpanah Y, Olsen IC, Costagliola D; EU SolidAct study group. Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial. Crit Care. 2023 Jan 10;27(1):9. doi: 10.1186/s13054-022-04205-8.
citation: Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.